Epalrestat Tablets

Name:Epalrestat Tablets

Specification:50mg*12

【Approval Number】State Drug Administration：H20234370

Usage and Dosage:

Treatment for the pathogenesis of neuropathy: aldose reductase inhibitors, commonly used drug is Epalrestat

Epalrestat: an aldose reductase inhibitor that inhibits the polyol pathway, improves metabolic disorders, and effectively improves the subjective symptoms and nerve conduction velocity of diabetic neuropathy.

Consensus recommendations for the treatment of diabetic neuropathy.

Blocking polyol pathway, preventing diabetic neuropathy from the source.

Clinically superior to lipoic acid/methylcobalamin in the treatment of diabetic neuropathy.

Early application can delay or prevent the onset of diabetic retinopathy/nephropathy.

Low adverse effects, high safety, long-term use, lasting benefits